The group's principal activities are to discover, develop and commercialize immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer. The group develops cancer therapies by combining its expertise in the biology of dendritic cells, monoclonal antibodies, immunology and antigen discovery. These therapies are derived from two product development programs dcvax (TM) and hurx (TM). The group is in its development stage.
